Please Wait
Applying Filters...
menu
    • menu
    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lorecivivint

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biosplice searches for a path forward osteoarthritis drug fails late-stage study
    Biosplice searches for a path forward osteoarthritis drug fails late-stage study

    22 Apr 2024

    // Jared Whitlock ENDPTS

    https://endpts.com/biosplice-searches-for-a-path-forward-after-osteoarthritis-drug-fails-late-stage-study/

    Jared Whitlock ENDPTS
    22 Apr 2024
    Share Share
    Biosplice: OA-07 P3 Lorecivivint Data At OARSI, OA-21 12-Wk Results
    Biosplice: OA-07 P3 Lorecivivint Data At OARSI, OA-21 12-Wk Results

    18 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/18/2865193/0/en/Biosplice-Announces-Upcoming-Presentation-of-Successful-OA-07-Phase-3-Long-Term-Structure-and-Pain-Function-Results-for-Lorecivivint-for-Treatment-of-Knee-Osteoarthritis-at-OARSI-C.html

    GLOBENEWSWIRE
    18 Apr 2024
    Share Share
    Biosplice Presents Results from Phase 3 Clinical Trial for Lorecivivint
    Biosplice Presents Results from Phase 3 Clinical Trial for Lorecivivint

    13 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/13/2778824/0/en/Biosplice-Presents-Successful-Structure-and-Pain-Results-from-Completed-Phase-3-Long-Term-Extension-Clinical-Trial-for-Lorecivivint-for-the-Treatment-of-Knee-Osteoarthritis.html

    GLOBENEWSWIRE
    13 Nov 2023
    Share Share
    Samumed & United Therapeutics Announce License Agreement For IPF Drug Candidate
    Samumed & United Therapeutics Announce License Agreement For IPF Drug Candidate

    17 Sep 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/samumed-and-united-therapeutics-announce-north-american-license-agreement-for-samumeds-ipf-drug-candidate-300713382.html

    PR NEWSWIRE
    17 Sep 2018
    Share Share